1996 - 97
- Company started with operations at Bollaram facility
1999
- Further expansion of Bollaram facility
2002
- WHO-GMP approvals for facilities
2004-05
- Started filing DMFs and COSs starting with EU and Canada
- Entered into strategic partnership with Acino
2006
- US-DMF filed for Amlodipine Besylate
2007
- Developed Raloxifene API & filed DMF/CEP
- USFDA approval for Bollaram facility
- EU-GMP for Amlodipine Besylate
2008-09
- All facilities were USFDA and EU - GMP approved
2012
- Started FDF facility in Jadcherla SEZ
- USFDA approval renewed for Vizag
2013
- Divested Jadcherla FDF facility to Mylan
- Started a new FDF company "Evertogen" in partnership with Organosyn
2015
- Facility was reinspected by USFDA with “zero “ Form 483 observations.
2016
- Sold Vizag facility to Torrent along with Raloxifene API & related DMF/CEP
2017
- Converted into a Pvt Ltd company
2018
- Acquired adjoining land (~6,300 sq mtrs) of the current manufacturing and constructed new warehouse, QC block & intermediate drying area to facilitate expansion, ease of operation and stricter compliances
2019
- Re-acquired Raloxifene API along with DMF/CEP from Torrent & signed a CMO agreement with Melody.
- The Facility was inspected and approved by TGA and PMDA.
2020
- The Facility was inspected (desktop) by USFDA by April/May 20. the inspection is closed / approved
- DMF for Amlodipine has been filed in China
- Added two new big clients for Amlodipine
2021
- New Pharma block added
- Expansion of intermediate manufacturing area
- Added one more Micronizer to increase productivity and with a view to have a separate dedicated micronation line for each product
